Edgewood Oncology, a clinical-stage biotechnology company focused on delivering BTX-A51 to patients with hematologic ...

Despite advancements in melanoma therapy, the prognosis remains unfavorable for many patients. The proteasome inhibitor MG132 has shown therapeutic potential through pathway regulation, yet its ...

黑色素瘤预后不佳，现有疗法存在耐药问题。研究人员探究蛋白酶体抑制剂 MG132 对黑色素瘤 A375 细胞的作用。发现 MG132 能抑制细胞增殖、迁移并诱导凋亡，其机制与 MDM2、p53 等相关。为黑色素瘤治疗提供新思路。

Scientists have long struggled to define brain fog—let alone pinpoint a cause for it. But research is starting to reveal multiple potential causes from inflammation to a leaky blood-brain ...